SWOG-9507, Fenretinide in Treating Patients With Neoplasia of the Mouth
A Single Arm, Phase II Study to Determine the Safety and Efficacy of 4-HPRN-(4-Hydroxyphenyl) Retinamide for Treating Oral Intraepithelial Neoplasia
Sponsor: National Cancer Institute (NCI)
Terminated
Closed due to poor accrual.
Other terminated trials from National Cancer Institute (NCI)
Other Head and Neck Cancer trials with similar outcome
A PHASE2 clinical study on Head and Neck Cancer, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 7 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
May 2023 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — May 2023 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 1997
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
- SWOG Cancer Research Network
For direct contact, visit the study record on ClinicalTrials.gov .